natgillin/translations-raw huggingface dataset:
The primary route of elimination is biliary excretion of parent molecule, with elimination through the faeces.
Glavni put izlučivanja je matična molekula u žuči u izmetu.
The primary route of excretion for lapatinib and its metabolites is in faeces.
Primarni put izlučivanja laptiniba i njegovih metabolita je stolicom.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Primarna mjera ishoda sigurnosti (neinferiornost) i djelotvornosti (superiornost) bila je kompozitna mjera ishoda koju je činilo vrijeme do prve pojave bilo kojeg od sljedećih velikih kardiovaskularnih štetnih događaja (engl. major adverse cardiac events, MACE): kardiovaskularna smrt, infarkt miokarda bez smrtnog ishoda ili ishemijski moždani udar bez smrtnog ishoda.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Primarna mjera ishoda sigurnosti (neinferiornost) i djelotvornosti (superiornost) bila je kompozitna mjera ishoda koju je činilo vrijeme do prve pojave bilo kojeg od sljedećih velikih kardiovaskularnih štetnih događaja (engl. major adverse cardiac events, MACE): kardiovaskularna smrt, infarkt miokarda bez smrtnog ishoda ili ishemijski moždani udarbez smrtnog ishoda.
The primary safety (noninferiority) and efficacy (superiority) endpoint was a composite endpoint consisting of the time-to-first occurrence of any of the following major adverse CV events (MACE): CV death, nonfatal myocardial infarction, or nonfatal ischemic stroke.
Primarna mjera ishoda sigurnosti (neinferiornost) i djelotvornosti (superiornost) bila je kompozitna mjera ishoda koju je činilo vrijeme do prve pojave bilo kojeg od sljedećih velikih kardiovaskularnih štetnih događaja (engl. major adverse cardiac events, MACE): kardiovaskularna smrt, infarkta miokarda bez smrtnog ishoda ili ishemijski moždani udar bez smrtnog ishoda.
The primary safety database is the Phase 3 clincal studies in which 662 subjects received 200 mg tedizolid phosphate orally and or intravenously (331/662 patients) for a maximum of 6 days.
Primarnu bazu podataka o sigurnosti predstavljaju klinička ispitivanja faze 3 u kojima je 662 ispitanika dobivalo 200 mg tedizolidfosfata peroralno i/ili intravenski (331/662 bolesnika) tijekom najviše 6 dana.
The primary safety database is the Phase 3 clinical studies in which 662 subjects received 200 mg tedizolid phosphate orally and/or intravenously (331/662 patients) for a maximum of 6 days.
Primarnu bazu podataka o sigurnosti predstavljaju klinička ispitivanja faze 3 u kojima je 662 ispitanika dobivalo 200 mg tedizolidfosfata peroralno i/ili intravenski (331/662 bolesnika) tijekom najviše 6 dana.
The primary safety endpoint was a composite of the following neuropsychiatric (NPS) adverse events: severe events of anxiety, depression, feeling abnormal, or hostility, and/or moderate or severe events of agitation, aggression, delusions, hallucinations, homicidal ideation, mania, panic, paranoia, psychosis, suicidal ideation, suicidal behaviour or completed suicide.
Primarni ishod bio je kombinacija sljedećih neuropsihijatrijskih (engl. neuropsychiatric, NPS) štetnih događaja: teški događaji tjeskobe, depresije, osjećaja abnormalnosti ili neprijateljstva i/ili umjereni ili teški događaji agitacije, agresije, deluzija, halucinacija, homicidalnih ideja, manije, panike, paranoje, psihoze, suicidalnih ideja, suicidalnog ponašanja ili ostvarenog samoubojstva.
The primary safety endpoint was major bleeding.
Primarni sigurnosni ishod bilo je značajno krvarenje.
The primary vaccination schedules used in clinical studies are: 2, 4 months of age without hepatitis B vaccination at birth; 2, 3, 4 months of age without hepatitis B vaccination at birth; 2, 4, 6 months of age with and without hepatitis B vaccination at birth.
Rasporedi primarnog cijepljenja korišteni u kliničkim studijama su sljedeći: u dobi od 2 i 4 mjeseca bez cijepljenja protiv hepatitisa B pri porodu; u dobi od 2, 3 i 4 mjeseca bez cijepljenja protiv hepatitisa B pri porodu; u dobi od 2, 4 i 6 mjeseci s i bez cijepljenja protiv hepatitisa B pri porodu.
The primary vaccination series consists of two separate doses of 0.5 ml each, according to the following conventional schedule:
Primarna serija cijepljenja sastoji se od dvije zasebne doze, svaka od po 0,5 ml, u skladu sa sljedećim standardnim rasporedom:
The principal action of 1,25 dihydroxyvitamin D3 is to increase intestinal absorption of both calcium and phosphate as well as regulate serum calcium, renal calcium and phosphate excretion, bone formation and bone resorption.
Osnovni način na koji djeluje 1,25-dihidroksivitamin D3 jest povećavanje apsorpcije kalcija i fosfata iz crijeva, reguliranje koncentracije kalcija u serumu, izlučivanje kalcija i fosfata bubrezima, formiranje i resorpcija kostiju.
The principal adverse reactions associated with the administration of CellCept in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting, and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavne nuspojave vezane uz primjenu lijeka CellCept u kombinaciji s ciklosporinom i kortikosteroidima su proljev, leukopenija, sepsa i povraćanje, a dokazana je veća učestalost određenih vrsta infekcija (vidjeti dio 4.4).
The principal adverse reactions associated with the administration of mycophenolate mofetil in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavne nuspojave, vezane uz primjenu mofetilmikofenolata u kombinaciji s ciklosporinom i kortikosteroidima, su proljev, leukopenija, sepsa i povraćanje, a dokazana je veća učestalost određenih vrsta infekcija (vidjeti dio 4.4).
The principal adverse reactions associated with the administration of mycophenolate mofetil in combination with ciclosporin and corticosteroids include diarrhoea, leucopenia, sepsis and vomiting, and there is evidence of a higher frequency of certain types of infections (see section 4.4).
Glavne nuspojave, vezane uz primjenu mofetilmikofenolata u kombinaciji s ciklosporinom i kortikosteroidima, su proljev, leukopenija, sepsa i povraćanje, a dokazana je veća učestalost određenih vrsta infekcija (vidjeti dio 4.4).
The principal analysis of the pivotal comparative study in 586 patients suffering from beta-thalassaemia and transfusional iron overload did not demonstrate non-inferiority of deferasirox dispersible tablets to deferoxamine in the analysis of the total patient population.
Glavna analiza rezultata ključnog komparativnog kliničkog ispitivanja na 586 bolesnika s beta- talasemijom i transfuzijskim preopterećenjem željezom nije dokazala neinferiornost deferasiroks tableta za oralnu suspenziju u odnosu na deferoksamin kada je u analizu bila uključena cijela populacija bolesnika.
The principal efficacy results at Day 35 from the controlled phase of each study are shown in Table 3.
Glavni rezultati za djelotvornost 35 dana nakon kontrolirane faze tih ispitivanja prikazani su u tablici 3.
The principal pathway involves hydrolytic oxidation of the amide moiety leading to the primary metabolite ‘safinamide acid’ (NW-1153).
Glavni put uključuje hidrolitičku oksidaciju amidne skupine što vodi prema primarnom metabolitu „safinamidnoj kiselini“ (NW-1153).
The principal radioactive component in both plasma and faeces was ospemifene and the main metabolite 4- hydroxyospemifene.
Glavna radioaktivna komponenta u plazmi i u fecesu bio je ospemifen, a glavni metabolit 4-hidroksiospemifen.
The principal route of metabolism was hydrolysis of the S- fluoromethyl carbothioate function to form the 17β-carboxylic acid metabolite.
Glavni put metabolizma je funkcija hidrolize S- fluorometilkarbotioata u cilju formiranja metabolita 17β-karboksilne kiseline.
The principal safety outcome (major bleeding) occurred in 6 (0.6 %) and 4 (0.8 %) patients in the rivaroxaban (n = 988) and VKA (n = 499) groups, respectively (RR 0.76; 95 % CI 0.21- 2.67; safety population).
Glavni cilj ispitivanja sigurnosti (veća krvarenja) pojavio se u 6 (0,6%) i 4 (0,8%) bolesnika na rivaroksabanu (n= 988), odnosno VKA (n= 499) (RR 0,76; 95% CI 0,21-2,67; sigurnosna populacija).
The principle mechanism of action of clomipramine is potentiation of the effects of 5-HT and noradrenaline in the brain by inhibiting their neuronal reuptake.
Glavni mehanizam djelovanja klomipramina je potencijacija učinaka 5-HT i noradrenalina u mozgu inhibicijom njihove ponovne pohrane u neuronima.
The principle route of excretion in dogs is via the bile (>80%) with the remainder via the urine.
Glavni put izlučivanja u pasa je putem žuči (> 80 %), dok se preostala količina izlučuje urinom.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Na tiskanoj uputi o lijeku mora mora se navesti naziv i adresa proizvođača odgovornog za puštanje navedene serije u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Na tiskanoj uputi o lijeku mora se navesti naziv i adresa proizvođača odgovornog za puštanje navedene serije u promet.‌
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Na tiskanoj uputi o lijeku mora se navesti naziv i adresa proizvođača odgovornog za puštanje serije lijeka u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Tiskana uputa o VMP mora sadržavati ime i adresu proizvođača odgovornog za puštanje odnosne serije u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Tiskana uputa o VMP mora sadržavati ime i adresu proizvođača odgovornog za puštanje serije u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Uputa o lijeku mora navoditi naziv i adresu proizvođača odgovornog za puštanje navedene serije lijeka u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Uputa o medicinskom proizvodu mora sadržavati ime i adresu proizvođača odgovornog za puštanje dotične serije u promet.
The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.‌
Na tiskanoj uputi o lijeku mora se navesti naziv i adresa proizvođača odgovornog za puštanje navedene serije u promet.
The printed package leaflet of the medicinal product must state the nameand address of the manufacturer responsible for the release of the concerned batch.
Na tiskanoj uputi o lijeku mora se navesti naziv i adresa proizvođača odgovornog za puštanje navedene serije u promet.
The printing ink contains iron oxide black (E172), isopropyl alcohol, propylene glycol and hypromellose (E464).
Tinta za označavanje sadrži crni željezov oksid (E172), izopropilni alkohol, propilenglikol i hipromelozu (E464).
The printing ink contains: shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527) (white ink) and shellac, iron oxide black (E172), propylene glycol (E1520) and ammonium hydroxide (E527) (black ink).
Tinta za označavanje sadrži: šelak, titanijev dioksid (E171), simetikon, propilenglikol (E1520) i amonijev hidroksid (E527) (bijela tinta) i šelak, crni željezov oksid (E172), propilenglikol (E1520) i amonijev hidroksid (E527) (crna tinta).
The printing ink contains: white ink - shellac, titanium dioxide (E171), simethicone, propylene glycol (E1520) and ammonium hydroxide (E527).
Tinta za označavanje sadrži: bijelu tintu - šelak, titanijev dioksid (E171), simetikon, propilenglikol (E1520) i amonijev hidroksid (E527).
The printing ink is composed of red iron oxide (E172) and shellac.
Tinta za označavanje se sastoji od crvenog željezovog oksida (E172) i šelaka.
The printing ink is composed of red iron oxide (E172), shellac, soya lecithin.
Tinta za označavanje se sastoji od crvenog željezovog oksida (E172), šelaka, sojinog lecitina.
The printing ink is composed of shellac, black iron oxide (E172) and propylene glycol.
Tinta za označavanje sastoji se od šelaka, crnog željezovog oksida (E172) i propilenglikola.
The printing ink is composed of shellac, iron oxide black (E172), N-butyl alcohol, purified water, propylene glycol and ammonium hydroxide.
Tinta za označavanje se sastoji od šelaka, crnog željezovog oksida (E172), N-butilnog alkohola, pročišćene vode, propilenglikola i amonijevog hidroksida..
The printing ink used to mark Advagraf capsules contains soya lecithin.
Tinta kojom su otisnute oznake na kapsulama Advagrafa sadrži sojin lecitin.
The pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter P-gp.
Predlijek dabigatraneteksilat, ali ne i dabigatran, supstrat je efluksnog prijenosnika P-gp.
The probability for sustained virological response varied depending upon the previous treatment regimen; see Table 19.
Vjerojatnost trajnog virološkog odgovora razlikovala se ovisno o prethodnom terapijskom režimu; vidjeti tablicu 19.
The probability of having an exacerbation in patients receiving Incruse at week 24 was 8.9% compared with 13.7% for placebo.
Vjerojatnost pojave egzacerbacije nakon 24 tjedna iznosila je 8,9% u bolesnika liječenih lijekom Incruse te 13,7% u onih koji su primali placebo.
The probability of survival at 1 year was 97%, at 2 years 93% and at 3 years 91%.
Vjerojatnost jednogodišnjeg preživljenja bila je 97%, dvogodišnjeg 93%, a trogodišnjeg 91%.
The probability of survival at 1 year was 97%, at 2 years 94% and at 3 years 88%.
Vjerojatnost jednogodišnjeg preživljenja bila je 97%, dvogodišnjeg 94%, a trogodišnjeg 88%.
The probability to require only one treatment with Ameluz and remain completely cleared 12 months later was 34.5% on average with all lamps.
Vjerojatnost da bolesnik treba samo jedno liječenje lijekom Ameluz a da ostane potpuno očišćen 12 mjeseci kasnije bila je u prosjeku 34,5% sa svim lampama.
The problem will usually go away but if it doesn’t, check with your doctor or pharmacist.
Ti problemi uobičajeno prestaju sami, ali ako ne prestanu, provjerite sa svojim liječnikom ili ljekarnikom.
The procedure should be carried out under sterile conditions.
Postupak se mora izvršiti u sterilnim uvjetima.
The procedure should be carried out under sterile conditions.
Postupak se mora provesti u sterilnim uvjetima.
The procedure should be carried out under sterile conditions.
Postupak treba provoditi pod sterilnim uvjetima.
The process of covalently conjugating a PEG moiety to a protein can alter the in vivo properties of the unmodified protein, including decreased renal clearance and decreased proteolysis thus extending the circulating half-life.
Postupak kovalentnog vezanjaPEG skupine na protein može mijenjati in vivo svojstva nemodificiranog proteina, uključujući smanjenje bubrežnog klirensa i smanjenu proteolizu čime se produljuje njegov poluvijek u cirkulaciji.
The product (cartridges in-use in the pump) may be stored for a maximum of 2 weeks.
Lijek (ulošci u uporabi koji se nalaze u pumpi) se može čuvati najdulje 2 tjedna.
The product can be stored for a single period of 2 months at a temperature not above 25°C, after which it must be discarded.
Lijek se može čuvati na temperaturi ispod 25°C jednokratno u razdoblju od 2 mjeseca, nakon čega se mora baciti.
The product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
Proizvod se može koristiti kao dio preventivnog programa za suzbijanje alergijskog dermatitisa uzrokovanog buhama.
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Proizvod se može koristiti kako bi se spriječio nastanak alergijskog dermatitisa uzrokovanog buhama (FAD).
The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
Proizvod se može koristiti kao dio strategije u suzbijanju alergijskog dermatitisa pasa uzrokovanog buhama (FAD).
The product can be used in chickens laying eggs for human consumption as it has been shown to have no adverse effects on egg formation or the laying process at the recommended treatment dose.
Proizvod se može koristiti u pilića koji nesu jaja za ljudsku upotrebu jer je dokazano da pri preporučenoj terapijskoj dozi nema nuspojava na formiranje jaja ili postupak nesenja.
The product consists of lipid encapsulated perflutren microspheres.
Proizvod se sastoji od mikrosfera perflutrena inkapsuliranih lipidom.
The product contains 100 International Units (IU) per ml (500 IU/5 ml or 1000 IU/10 ml) human coagulation factor IX when reconstituted with 5 ml or 10 ml, respectively, of water for injections.
Lijek sadrži 100 internacionalnih jedinica (IU) po ml (500 IU/5 ml ili 1000 IU/10 ml) ljudskog faktora koagulacije IX nakon pripreme s 5 ml ili 10 ml vode za injekcije.
The product contains less than 1 mmol (39 mg) potassium per administration of 27-60 injection sites ; i.e. essentially potassium-free.
Lijek sadrži manje od 1 mmol (39 mg) kalija po primjeni na 27–60 mjesta injiciranja, tj. sadrži zanemarivu količinu kalija.
The product contains traces of mouse proteins.
Lijek sadrži proteine miša u tragovima.
The product contributes towards the control of the environmental flea populations in areas to which treated cats have access.
Proizvod pomaže kontroli populacije buha u okolini tretiranih mačaka.
The product contributes towards the control of the environmental flea populations in areas to which treated dogs have access.
Proizvod pomaže kontroli populacije buha u okolini tretiranog psa.
The product dissolves rapidly (usually in less than 1 minute).
Prašak se brzo otapa (obično za manje od 1 minute).
The product does not contain a preservative, and the reconstituted product should be used immediately, or within 3 hours after reconstitution or removal of the grey tip cap.
Ovaj lijek ne sadrži konzervanse te se rekonstituirani lijek treba primijeniti odmah ili u roku od 3 sata od rekonstitucije ili uklanjanja sivog zatvarača s vrha štrcaljke.
The product has a long duration of action; however, the exact clinical effect duration after a single injection is unknown.
Proizvod ima dugotrajno djelovanje, međutim trajanje kliničkog učinka nakon jedne injekcije je nepoznato.
The product has been shown to be stable to the pelleting process at temperatures of 75 °C. Aggressive pelleting conditions such as temperatures in excess of 80 °C, and the use of abrasive substances for pre- mixture should be avoided.
Proizvod se pokazao stabilnim u procesu peletiranja pri temperaturi od 75°C. Agresivne uvjete peletiranja, kao što su temperature iznad 80°C i uporaba abrazivnih tvari, poput premiksa treba izbjegavati.
The product has been shown to be stable to the pelleting process at temperatures of 75 °C. Aggressive pelleting conditions such as temperatures in excess of 80 °C, and the use of abrasive substances for pre-mixture should be avoided.
Proizvod se pokazao stabilnim u procesu peletiranja pri temperaturi od 75°C. Agresivne uvjete peletiranja, kao što su temperature iznad 80°C i primjena abrazivnih tvari, poput premiksa treba izbjegavati.
The product has been used in combination with phenobarbital in a small number of cases and no harmful clinical interactions were observed.
U malom broju slučajeva proizvod je primjenjivan u kombinaciji s fenobarbitalom i nisu opažene štetne kliničke interakcije.
The product has been used in combination with phenobarbital in a small number of cases and no harmful clinical interactions were observed.
U malom broju slučajeva, proizvod je primjenjivan u kombinaciji s fenobarbitalom i nisu opažene štetne kliničke interakcije.
The product has persistent acaricidal efficacy for up to 5 weeks against Ixodes ricinus and up to 3 weeks against Rhipicephalus sanguineus.
Proizvod ima trajnu akaricidnu djelotvornost do 5 tjedana protiv Ixodes ricinus i do 3 tjedna protiv infestacija Rhipicephalus sanguineus.
The product information (Sections 4.4 and 4.8 of the SmPC) provides already information on clinical trial results in which showed an increased fracture risk in women only.
Informacije o lijeku (dijelovi 4.4 i 4.8 Sažetka opisa svojstava lijeka) već navode podatke o rezultatima kliničkih ispitivanja koji su pokazali povećani rizik prijeloma samo u žena.
The product information of the relevant Canigen vaccines should be consulted before administration of the mixed product.
Prije aplikacije Caningen L4 u kombinaciji sa odgovarajućim Caningen cjepivima potrebno je pročitati uputu o proizvodu sa kojim se cjepivo miješa.
The product information of the relevant Nobivac vaccines should be consulted before administration of the mixed product.
Informacije o cjepivima Nobivac treba provjeriti prije primjene pomiješanih proizvoda.
The product information of UNISTRAIN PRRS should be consulted before administration of the mixed products.
Prije primjene pomiješanih proizvoda potrebno je pročitati upute uz VMP UNISTRAIN PRRS.
The product integrity has been breached in anyway.
Integritet lijeka je narušen na bilo koji način.
The product is a clear, colourless to pale yellow solution for injection containing 15 mg pegbovigrastim (pegylated bovine colony stimulating factor) in a pre-filled syringe.
Proizvod je bistra, bezbojna do blijedo žuta otopina za injekciju koja sadrži 15 mg pegbovigrastima (pegilirani goveđi faktor stimulacije granulocitnih kolonija) u napunjenoj štrcaljki.
The product is activated upon contact with fluid, and adheres and conforms to tissue.
Lijek se nakon dodira s tekućinom aktivira, te prianja i prilagođuje se tkivu.
The product is available in a single pack of either 5 ml or 20 ml, composed of a vial containing the freeze- dried powder, and a second vial containing the diluent.
Proizvod je dostupan u jediničnom pakovanju od 5 mL ili 20 mL sastavljenom od bočice s liofiliziranim praškom i druge bočice s otapalom.
The product is available in different sizes and comes in packages with up to 5 units: Package with 1 matrix of 9.5 cm x 4.8 cm
Lijek je dostupan u različitim veličinama i pakiranjima do 5 komada: Pakiranje sa 1 matricom od 9,5 cm x 4,8 cm
The product is for in-patient administration only.
Lijek je samo za primjenu na hospitaliziranim bolesnicima.
The product is for skin application on dogs only; do not put in your dog’s mouth.
Ovaj proizvod je za kožnu primjenu samo na psima, nemojte ga stavljati u pseća usta.
The product is highly flammable.
Ovaj proizvod je lako zapaljiv.
The product is highly flammable.
Proizvod je veoma zapaljiv.
The product is made from human plasma (the liquid part of the blood) and contains the active substances called human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF).
Lijek se dobiva iz ljudske plazme (plazma je tekući dio krvi) i sadrži aktivne tvari koje se nazivaju faktor zgrušavanja VIII ljudskog podrijetla (FVIII) i von Willebrandov faktor ljudskog podrijetla (VWF) kao djelatne tvari.
The product is made from human plasma (the liquid part of the blood) and contains the active substances called human coagulation factor VIII (FVIII) and human von Willebrand factor (VWF).
Lijek se dobiva iz ljudske plazme (plazma je tekući dio krvi) i sadrži aktivne tvari koje se nazivaju ljudski faktor zgrušavanja VIII (FVIII) i ljudski von Willebrandov faktor (VWF) kao djelatne tvari.